The Goldman Sachs Group Increases Agios Pharmaceuticals (NASDAQ:AGIO) Price Target to $33.00

Agios Pharmaceuticals (NASDAQ:AGIO) had its target price upped by equities researchers at The Goldman Sachs Group from $29.00 to $33.00 in a research report issued to clients and investors on Friday, Benzinga reports. The brokerage presently has a “neutral” rating on the biopharmaceutical company’s stock. The Goldman Sachs Group’s price objective would indicate a potential downside of 4.46% from the company’s current price.

AGIO has been the topic of several other research reports. Royal Bank of Canada reduced their target price on shares of Agios Pharmaceuticals from $43.00 to $42.00 and set an “outperform” rating on the stock in a report on Friday, February 16th. JPMorgan Chase & Co. lowered their target price on Agios Pharmaceuticals from $31.00 to $30.00 and set a “neutral” rating for the company in a research note on Friday, February 23rd. Finally, Cantor Fitzgerald reissued an “overweight” rating on shares of Agios Pharmaceuticals in a research report on Tuesday, April 9th. One research analyst has rated the stock with a sell rating, two have assigned a hold rating and two have assigned a buy rating to the company. Based on data from MarketBeat.com, the company presently has a consensus rating of “Hold” and a consensus target price of $34.75.

Agios Pharmaceuticals Trading Down 0.1 %

Shares of Agios Pharmaceuticals stock opened at $34.54 on Friday. The stock has a market capitalization of $1.96 billion, a P/E ratio of -5.47 and a beta of 0.81. The business’s fifty day moving average price is $30.61 and its 200 day moving average price is $25.65. Agios Pharmaceuticals has a twelve month low of $19.80 and a twelve month high of $35.50.

Agios Pharmaceuticals (NASDAQ:AGIO) last posted its earnings results on Thursday, May 2nd. The biopharmaceutical company reported ($1.45) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($1.64) by $0.19. The firm had revenue of $8.19 million during the quarter, compared to the consensus estimate of $8.37 million. Agios Pharmaceuticals had a negative net margin of 1,199.26% and a negative return on equity of 39.74%. The company’s revenue was up 46.0% on a year-over-year basis. During the same quarter in the prior year, the company earned ($1.47) EPS. As a group, sell-side analysts predict that Agios Pharmaceuticals will post -5.29 EPS for the current year.

Insider Transactions at Agios Pharmaceuticals

In other Agios Pharmaceuticals news, CEO Brian Goff sold 4,156 shares of the firm’s stock in a transaction that occurred on Tuesday, March 5th. The stock was sold at an average price of $32.57, for a total transaction of $135,360.92. Following the completion of the sale, the chief executive officer now owns 53,780 shares in the company, valued at approximately $1,751,614.60. The sale was disclosed in a legal filing with the SEC, which is available through the SEC website. In other Agios Pharmaceuticals news, CEO Brian Goff sold 4,156 shares of the firm’s stock in a transaction on Tuesday, March 5th. The shares were sold at an average price of $32.57, for a total transaction of $135,360.92. Following the completion of the transaction, the chief executive officer now directly owns 53,780 shares of the company’s stock, valued at approximately $1,751,614.60. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, insider James William Burns sold 2,642 shares of the company’s stock in a transaction dated Tuesday, March 5th. The shares were sold at an average price of $32.57, for a total transaction of $86,049.94. Following the completion of the sale, the insider now owns 34,518 shares in the company, valued at approximately $1,124,251.26. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 16,035 shares of company stock valued at $475,277. 4.24% of the stock is currently owned by insiders.

Institutional Inflows and Outflows

Hedge funds have recently made changes to their positions in the company. Assenagon Asset Management S.A. lifted its stake in Agios Pharmaceuticals by 800.5% during the first quarter. Assenagon Asset Management S.A. now owns 454,801 shares of the biopharmaceutical company’s stock worth $13,298,000 after purchasing an additional 404,297 shares during the last quarter. Norges Bank bought a new position in shares of Agios Pharmaceuticals in the 4th quarter worth about $6,826,000. Frazier Life Sciences Management L.P. grew its position in shares of Agios Pharmaceuticals by 79.2% during the 4th quarter. Frazier Life Sciences Management L.P. now owns 523,166 shares of the biopharmaceutical company’s stock valued at $11,651,000 after buying an additional 231,164 shares during the last quarter. Armistice Capital LLC lifted its holdings in Agios Pharmaceuticals by 6.0% in the fourth quarter. Armistice Capital LLC now owns 3,524,000 shares of the biopharmaceutical company’s stock worth $78,479,000 after acquiring an additional 200,000 shares during the last quarter. Finally, Dimensional Fund Advisors LP boosted its stake in Agios Pharmaceuticals by 5.6% in the fourth quarter. Dimensional Fund Advisors LP now owns 2,596,764 shares of the biopharmaceutical company’s stock valued at $57,832,000 after acquiring an additional 137,873 shares during the period.

About Agios Pharmaceuticals

Agios Pharmaceuticals, Inc, a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes for the treatment of hemolytic anemias.